Hedge Fund and Insider Trading News: David Einhorn, Silver Lake Partners, Bellerophon Therapeutics Inc (BLPH), Titan Pharmaceuticals, Inc. (TTNP), Spark Energy Inc (SPKE) and More

Insider Buying: Bellerophon Therapeutics Inc (BLPH) Major Shareholder Purchases 200,000 Shares of Stock (XNewsPress.com)
Bellerophon Therapeutics Inc (NASDAQ:BLPH) major shareholder Associates Iv L. P. Venrock purchased 200,000 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The shares were bought at an average price of $1.22 per share, with a total value of $244,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission.

Insider Buying: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Insider Buys 300,000 Shares of Stock (FairFieldCurrent.com)
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) insider Sunil Bhonsle acquired 300,000 shares of the business’s stock in a transaction on Friday, September 21st. The shares were purchased at an average price of $0.25 per share, with a total value of $75,000.00. Following the transaction, the insider now owns 435,578 shares in the company, valued at approximately $108,894.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Insider Buying: Spark Energy Inc (SPKE) Director Acquires $1,016,012.80 in Stock (MareaInformativa.com)
Spark Energy Inc (NASDAQ:SPKE) Director W Keith Maxwell III bought 123,904 shares of the business’s stock in a transaction on Friday, September 28th. The shares were acquired at an average price of $8.20 per share, with a total value of $1,016,012.80. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Insider Selling: RealPage Inc (RP) CEO Sells 150,000 Shares of Stock (PressOracle.com)
RealPage Inc (NASDAQ:RP) CEO Stephen T. Winn sold 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $64.62, for a total value of $9,693,000.00. Following the completion of the sale, the chief executive officer now directly owns 1,086,819 shares of the company’s stock, valued at $70,230,243.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission.

Insider Buying: Odonate Therapeutics Inc (NASDAQ:ODT) CEO Purchases 40,000 Shares of Stock (FairFieldCurrent.com)
Odonate Therapeutics Inc (NASDAQ:ODT) CEO Kevin C. Tang purchased 40,000 shares of the stock in a transaction on Wednesday, September 26th. The shares were purchased at an average cost of $19.75 per share, for a total transaction of $790,000.00. The acquisition was disclosed in a filing with the SEC.